BORDEAUX, France–(BUSINESS WIRE)–FineHeart today announced that it has been named by FierceMedTech as one of 2018’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
FineHeart’s technology, the ICOMS (Implantable Cardiac Output Management System), is dedicated to the treatment of severe heart failure patients: it is a novel, wirelessly powered, fully implantable, pulsatile mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility. The overreaching goal is to restore normal cardiac output and allow heart failure patients to return to a normal quality of life.
“FineHeart is honored to be named among the ‘Fierce 15’ Med Tech Companies of 2018,” commented Arnaud Mascarell, CEO. “This recognition reflects the significant commercial potential of ICOMS for the treatment of heart failure, the second leading cause of mortality in G20 countries. The ICOMS will not only compete with existing devices but will also extend to currently unaddressed heart failure populations.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceMedTech’s 7th annual Fierce 15 selection. This year’s full list of winners can be viewed online at https://www.fiercebiotech.com/special-report/fiercemedtech-s-2018-fierce-15.
An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, FierceMedTechprovides subscribers with an authoritative analysis of the day’s top stories. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers, and a competitive market position.
FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on FierceMedTechfor an insider briefing on the day’s top stories.
FineHeart is a French medical device company founded by a team of internationally renowned cardiac surgeons and cardiologists together with experienced managers in the cardiovascular device industry. They adopted a vision of making a miniaturized, fully implantable, pulsatile circulatory support system that would overcome most of the challenges associated with left ventricular assist devices (LVADs) currently on the market. For more information, visit: http://fineheart.fr/